Gender susceptibility to COVID-19: a review of the putative role of sex hormones and X chromosome.
ACE2
COVID-19
TMPRSS2
Journal
Journal of endocrinological investigation
ISSN: 1720-8386
Titre abrégé: J Endocrinol Invest
Pays: Italy
ID NLM: 7806594
Informations de publication
Date de publication:
May 2021
May 2021
Historique:
received:
09
06
2020
accepted:
31
07
2020
pubmed:
17
9
2020
medline:
23
4
2021
entrez:
16
9
2020
Statut:
ppublish
Résumé
The recent emergence of COVID-19 poses a global health emergency. One of the most frequently reported data is sex-related severity and mortality: according to the last available analysis on 239,709 patients in Italy, lethality is 17.7% in men and 10.8% in women, with 59% of total deaths being men. Interestingly, the infection rate is lower in males than in females, with 45.8% and 54.2% of positive cases, respectively, suggesting that gender-related factor may worsen disease evolution. A tentative hypothesis to explain these findings is the role of angiotensin-converting enzyme 2 (ACE2) and serine protease TMPRSS2 involved in viral infection. In this review, we summarize the available evidence pointing to gender-related differences in ACE2 and TMPRSS2 expression, from both genetic and endocrine points of view. Altogether, available evidence points toward two not-mutually exclusive mechanisms in gender susceptibility to COVID-19 by sex hormonal regulation of ACE2 and TMPRSS2. On one hand, ACE2 expression could be increased in women, either by estrogens or constitutively by X chromosome inactivation escape or by reduced methylation, providing a larger reservoir of ACE2 to maintain the fundamental equilibrium of RAS regulatory axis. On the other, low levels of androgens in women may keep at low levels TMPRSS2 expression, representing a further protective factor for the development of COVID-19 infection, despite the increased expression of ACE2, which represents the Trojan horse for SARS-CoV-2 entry. Both mechanisms consistently point to the role of sex hormones and sex chromosomes in the differential severity and lethality of COVID-19 in men and women.
Sections du résumé
BACKGROUND
BACKGROUND
The recent emergence of COVID-19 poses a global health emergency. One of the most frequently reported data is sex-related severity and mortality: according to the last available analysis on 239,709 patients in Italy, lethality is 17.7% in men and 10.8% in women, with 59% of total deaths being men. Interestingly, the infection rate is lower in males than in females, with 45.8% and 54.2% of positive cases, respectively, suggesting that gender-related factor may worsen disease evolution. A tentative hypothesis to explain these findings is the role of angiotensin-converting enzyme 2 (ACE2) and serine protease TMPRSS2 involved in viral infection.
PURPOSE
OBJECTIVE
In this review, we summarize the available evidence pointing to gender-related differences in ACE2 and TMPRSS2 expression, from both genetic and endocrine points of view.
RESULTS
RESULTS
Altogether, available evidence points toward two not-mutually exclusive mechanisms in gender susceptibility to COVID-19 by sex hormonal regulation of ACE2 and TMPRSS2. On one hand, ACE2 expression could be increased in women, either by estrogens or constitutively by X chromosome inactivation escape or by reduced methylation, providing a larger reservoir of ACE2 to maintain the fundamental equilibrium of RAS regulatory axis. On the other, low levels of androgens in women may keep at low levels TMPRSS2 expression, representing a further protective factor for the development of COVID-19 infection, despite the increased expression of ACE2, which represents the Trojan horse for SARS-CoV-2 entry.
CONCLUSIONS
CONCLUSIONS
Both mechanisms consistently point to the role of sex hormones and sex chromosomes in the differential severity and lethality of COVID-19 in men and women.
Identifiants
pubmed: 32936429
doi: 10.1007/s40618-020-01383-6
pii: 10.1007/s40618-020-01383-6
pmc: PMC7492232
doi:
Substances chimiques
Gonadal Steroid Hormones
0
ACE2 protein, human
EC 3.4.17.23
Angiotensin-Converting Enzyme 2
EC 3.4.17.23
Serine Endopeptidases
EC 3.4.21.-
TMPRSS2 protein, human
EC 3.4.21.-
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
951-956Références
PLoS One. 2015 May 26;10(5):e0127515
pubmed: 26010093
J Endocrinol Invest. 2020 Aug;43(8):1153-1157
pubmed: 32462316
Front Cell Dev Biol. 2019 Oct 22;7:241
pubmed: 31696116
Ann Oncol. 2020 Aug;31(8):1040-1045
pubmed: 32387456
J Virol. 2009 Apr;83(7):3200-11
pubmed: 19158246
Nature. 1961 Apr 22;190:372-3
pubmed: 13764598
Mol Med Rep. 2017 Jun;15(6):3905-3911
pubmed: 28440441
Nature. 2005 Jul 7;436(7047):112-6
pubmed: 16001071
BMJ. 2020 Mar 26;368:m1091
pubmed: 32217556
PLoS One. 2012;7(4):e35876
pubmed: 22558251
Ann Intern Med. 2003 Nov 4;139(9):715-23
pubmed: 14597455
China CDC Wkly. 2020 Feb 21;2(8):113-122
pubmed: 34594836
Biol Reprod. 2020 Jun 23;103(1):4-6
pubmed: 32297920
J Hypertens. 2012 Feb;30(2):375-83
pubmed: 22179088
Arterioscler Thromb Vasc Biol. 2012 Jun;32(6):1392-9
pubmed: 22460555
Nature. 2017 Oct 11;550(7675):244-248
pubmed: 29022598
Nature. 2020 Mar;579(7798):270-273
pubmed: 32015507
J Endocrinol Invest. 2020 Dec;43(12):1819-1822
pubmed: 32329026
Nat Commun. 2014 May 06;5:3594
pubmed: 24800825
Cancer Res. 1999 Sep 1;59(17):4180-4
pubmed: 10485450
Exp Biol Med (Maywood). 2017 Aug;242(14):1412-1423
pubmed: 28661206
Int J Infect Dis. 2020 Apr;93:264-267
pubmed: 32114193
J Clin Med. 2020 Mar 30;9(4):
pubmed: 32235486
Life Sci. 2006 Apr 4;78(19):2166-71
pubmed: 16303146
Andrology. 2021 Jan;9(1):27-29
pubmed: 32452644
JAMA. 2020 Jun 16;323(23):2427-2429
pubmed: 32432657
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
Endocrinology. 2004 Oct;145(10):4703-11
pubmed: 15231706
J Immunol. 2017 May 15;198(10):4046-4053
pubmed: 28373583
Nature. 2003 Nov 27;426(6965):450-4
pubmed: 14647384
Aging Cell. 2020 Jul;19(7):
pubmed: 32558150
Hum Genet. 2011 Aug;130(2):237-45
pubmed: 21614513
Cancer Discov. 2020 Jun;10(6):779-782
pubmed: 32276929
J Virol. 2010 Dec;84(24):12658-64
pubmed: 20926566
Andrology. 2021 Jan;9(1):23-26
pubmed: 32453494
Andrology. 2021 Jan;9(1):88-98
pubmed: 32436355
Drug Dev Res. 2020 Aug;81(5):537-540
pubmed: 32129518
Hum Mol Genet. 2001 Oct 1;10(20):2225-32
pubmed: 11673405
Biochim Biophys Acta. 1984 Sep 10;782(4):331-42
pubmed: 6383476
Cell. 2020 Apr 16;181(2):271-280.e8
pubmed: 32142651
BMJ. 2020 Apr 21;369:m1443
pubmed: 32317267
Chin Med J (Engl). 2020 May 5;133(9):1039-1043
pubmed: 32118639